Augmenting T helper cell immunity in cancer

Keith L Knutson, M. L. Disis

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Cancer specific immunity elicited with vaccines has traditionally focused on the activation of the CD8 cytolytic T lymphocyte (CTL) often involving direct stimulation of immunity using HLA-class I binding peptide epitopes. Recently it has become clear that activation of the CTL immune effector arm alone is insufficient to mediate an anticancer response. A major problem is that CD8 T cells alone can not be sustained without the concomitant activation of CD4 T helper (Th) cells. In fact, it is now widely recognized that the Th cell regulates nearly all aspects of the adaptive immune response. In addition, Th cells can recruit the innate immune system during immune augmentation. Therefore, the focus of the immune response in cancer has shifted away from activating CTL immunity alone to activating Th cell immunity alone or concurrently with CTL. Evidence suggests that activating the Th cell is sufficient to get a complete adaptive immune response because, once activated, the Th cell will elicit endogenous CD8 T cell and humoral immunity. In this review, we discuss the role of the Th cell in the adaptive immune response to cancer, how peptides that are capable of activation of Th cells are identified, and the clinical translation of newly identified candidate Th cell peptide epitopes to human cancer specific vaccines. Over the next decade, studies should begin to further define how we can manipulate the Th immune effector arm to achieve effective antitumor immunity.

Original languageEnglish (US)
Pages (from-to)365-371
Number of pages7
JournalCurrent Drug Targets: Immune, Endocrine and Metabolic Disorders
Volume5
Issue number4
DOIs
StatePublished - Dec 2005

Fingerprint

Helper-Inducer T-Lymphocytes
Immunity
T-Lymphocytes
Neoplasms
Adaptive Immunity
Peptides
Epitopes
Cancer Vaccines
Humoral Immunity
Immune System
Vaccines

Keywords

  • Algorithms
  • Cancer
  • CD4 T cell
  • Epitope
  • Helper T cell
  • Immunotherapy
  • Tumor antigen
  • Vaccines

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy

Cite this

Augmenting T helper cell immunity in cancer. / Knutson, Keith L; Disis, M. L.

In: Current Drug Targets: Immune, Endocrine and Metabolic Disorders, Vol. 5, No. 4, 12.2005, p. 365-371.

Research output: Contribution to journalArticle

@article{a8a26f82a1e240c5b77e9e2baab7d457,
title = "Augmenting T helper cell immunity in cancer",
abstract = "Cancer specific immunity elicited with vaccines has traditionally focused on the activation of the CD8 cytolytic T lymphocyte (CTL) often involving direct stimulation of immunity using HLA-class I binding peptide epitopes. Recently it has become clear that activation of the CTL immune effector arm alone is insufficient to mediate an anticancer response. A major problem is that CD8 T cells alone can not be sustained without the concomitant activation of CD4 T helper (Th) cells. In fact, it is now widely recognized that the Th cell regulates nearly all aspects of the adaptive immune response. In addition, Th cells can recruit the innate immune system during immune augmentation. Therefore, the focus of the immune response in cancer has shifted away from activating CTL immunity alone to activating Th cell immunity alone or concurrently with CTL. Evidence suggests that activating the Th cell is sufficient to get a complete adaptive immune response because, once activated, the Th cell will elicit endogenous CD8 T cell and humoral immunity. In this review, we discuss the role of the Th cell in the adaptive immune response to cancer, how peptides that are capable of activation of Th cells are identified, and the clinical translation of newly identified candidate Th cell peptide epitopes to human cancer specific vaccines. Over the next decade, studies should begin to further define how we can manipulate the Th immune effector arm to achieve effective antitumor immunity.",
keywords = "Algorithms, Cancer, CD4 T cell, Epitope, Helper T cell, Immunotherapy, Tumor antigen, Vaccines",
author = "Knutson, {Keith L} and Disis, {M. L.}",
year = "2005",
month = "12",
doi = "10.2174/156800805774913006",
language = "English (US)",
volume = "5",
pages = "365--371",
journal = "Endocrine, Metabolic and Immune Disorders - Drug Targets",
issn = "1871-5303",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Augmenting T helper cell immunity in cancer

AU - Knutson, Keith L

AU - Disis, M. L.

PY - 2005/12

Y1 - 2005/12

N2 - Cancer specific immunity elicited with vaccines has traditionally focused on the activation of the CD8 cytolytic T lymphocyte (CTL) often involving direct stimulation of immunity using HLA-class I binding peptide epitopes. Recently it has become clear that activation of the CTL immune effector arm alone is insufficient to mediate an anticancer response. A major problem is that CD8 T cells alone can not be sustained without the concomitant activation of CD4 T helper (Th) cells. In fact, it is now widely recognized that the Th cell regulates nearly all aspects of the adaptive immune response. In addition, Th cells can recruit the innate immune system during immune augmentation. Therefore, the focus of the immune response in cancer has shifted away from activating CTL immunity alone to activating Th cell immunity alone or concurrently with CTL. Evidence suggests that activating the Th cell is sufficient to get a complete adaptive immune response because, once activated, the Th cell will elicit endogenous CD8 T cell and humoral immunity. In this review, we discuss the role of the Th cell in the adaptive immune response to cancer, how peptides that are capable of activation of Th cells are identified, and the clinical translation of newly identified candidate Th cell peptide epitopes to human cancer specific vaccines. Over the next decade, studies should begin to further define how we can manipulate the Th immune effector arm to achieve effective antitumor immunity.

AB - Cancer specific immunity elicited with vaccines has traditionally focused on the activation of the CD8 cytolytic T lymphocyte (CTL) often involving direct stimulation of immunity using HLA-class I binding peptide epitopes. Recently it has become clear that activation of the CTL immune effector arm alone is insufficient to mediate an anticancer response. A major problem is that CD8 T cells alone can not be sustained without the concomitant activation of CD4 T helper (Th) cells. In fact, it is now widely recognized that the Th cell regulates nearly all aspects of the adaptive immune response. In addition, Th cells can recruit the innate immune system during immune augmentation. Therefore, the focus of the immune response in cancer has shifted away from activating CTL immunity alone to activating Th cell immunity alone or concurrently with CTL. Evidence suggests that activating the Th cell is sufficient to get a complete adaptive immune response because, once activated, the Th cell will elicit endogenous CD8 T cell and humoral immunity. In this review, we discuss the role of the Th cell in the adaptive immune response to cancer, how peptides that are capable of activation of Th cells are identified, and the clinical translation of newly identified candidate Th cell peptide epitopes to human cancer specific vaccines. Over the next decade, studies should begin to further define how we can manipulate the Th immune effector arm to achieve effective antitumor immunity.

KW - Algorithms

KW - Cancer

KW - CD4 T cell

KW - Epitope

KW - Helper T cell

KW - Immunotherapy

KW - Tumor antigen

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=28444462530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28444462530&partnerID=8YFLogxK

U2 - 10.2174/156800805774913006

DO - 10.2174/156800805774913006

M3 - Article

VL - 5

SP - 365

EP - 371

JO - Endocrine, Metabolic and Immune Disorders - Drug Targets

JF - Endocrine, Metabolic and Immune Disorders - Drug Targets

SN - 1871-5303

IS - 4

ER -